NYMXF (Nymox Pharmaceutical) Cyclically Adjusted FCF per Share: $-0.13 (As of Dec. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Nymox Pharmaceutical Cyclically Adjusted FCF per Share?

Nymox Pharmaceutical NYMXF +1.00% Cyclically Adjusted FCF per Share is $-0.13 as of Dec. 2024.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Nymox Pharmaceutical's adjusted free cash flow per share for the three months ended in Dec. 2024 was $-0.008. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-0.13 for the trailing ten years ended in Dec. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-07-27), Nymox Pharmaceutical's current stock price is $0.0101. Nymox Pharmaceutical's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2024 was $-0.13. Nymox Pharmaceutical's Cyclically Adjusted Price-to-FCF of today is .


Nymox Pharmaceutical  (OTCPK:NYMXF) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Nymox Pharmaceutical Cyclically Adjusted FCF per Share Related Terms


Nymox Pharmaceutical Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Nymox Pharmaceutical's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nymox Pharmaceutical Cyclically Adjusted FCF per Share Chart

Nymox Pharmaceutical Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.18 -0.16 -0.15 -0.13 -0.13

Nymox Pharmaceutical Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Sep24 Dec24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.14 -0.13 -0.13 0.00 -0.13

NYMXF vs LYRA, RNAZ, TOVX: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Nymox Pharmaceutical's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nymox Pharmaceutical Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nymox Pharmaceutical's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Nymox Pharmaceutical's Cyclically Adjusted Price-to-FCF falls into.



Nymox Pharmaceutical Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Nymox Pharmaceutical's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=-0.008/315.6050*315.6050
=-0.008

Current CPI (Dec. 2024) = 315.6050.

Nymox Pharmaceutical Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201409 -0.045 238.031 -0.060
201412 -0.031 234.812 -0.042
201503 -0.011 236.119 -0.015
201506 -0.024 238.638 -0.032
201509 -0.030 237.945 -0.040
201512 -0.034 236.525 -0.045
201603 -0.037 238.132 -0.049
201606 -0.015 241.018 -0.020
201609 -0.014 241.428 -0.018
201612 -0.031 241.432 -0.041
201703 -0.015 243.801 -0.019
201706 -0.034 244.955 -0.044
201709 -0.046 246.819 -0.059
201712 -0.023 246.524 -0.029
201803 -0.032 249.554 -0.040
201806 -0.032 251.989 -0.040
201809 -0.039 252.439 -0.049
201812 -0.026 251.233 -0.033
201903 -0.024 254.202 -0.030
201906 -0.031 256.143 -0.038
201909 -0.027 256.759 -0.033
201912 -0.026 256.974 -0.032
202003 -0.030 258.115 -0.037
202006 -0.030 257.797 -0.037
202009 -0.054 260.280 -0.065
202012 -0.022 260.474 -0.027
202103 -0.034 264.877 -0.041
202106 -0.023 271.696 -0.027
202109 -0.036 274.310 -0.041
202112 -0.027 278.802 -0.031
202203 -0.049 287.504 -0.054
202206 0.015 296.311 0.016
202209 -0.014 296.808 -0.015
202212 -0.014 296.797 -0.015
202303 -0.011 301.836 -0.012
202306 -0.010 305.109 -0.010
202309 -0.014 307.789 -0.014
202312 -0.010 306.746 -0.010
202409 0.000 315.301 0.000
202412 -0.008 315.605 -0.008

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $-0.13 mean?
Nymox Pharmaceutical (NYMXF) has a Cyclically Adjusted FCF per Share of $-0.13 as of Dec. 2024. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Nymox Pharmaceutical and its competitors.
Is Nymox Pharmaceutical's Cyclically Adjusted FCF per Share too high?
Nymox Pharmaceutical's current Cyclically Adjusted FCF per Share is $-0.13.
How does Nymox Pharmaceutical's Cyclically Adjusted FCF per Share compare to LYRA and RNAZ?
Nymox Pharmaceutical's Cyclically Adjusted FCF per Share of $-0.13 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Nymox Pharmaceutical and its competitors. Nymox Pharmaceutical's current Cyclically Adjusted FCF per Share is $-0.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nymox Pharmaceutical stock overvalued right now?
Nymox Pharmaceutical (NYMXF) has a current Cyclically Adjusted FCF per Share of $-0.13. The current Cyclically Adjusted FCF per Share is $-0.13. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Nymox Pharmaceutical (NYMXF), the current Cyclically Adjusted FCF per Share is $-0.13 as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nymox Pharmaceutical Business Description

Address Bay & Deveaux Streets, Nassau, BHS
Nymox Pharmaceutical Corp is a biopharmaceutical company focused on developing its drug candidate, NX-1207, for the treatment of BPH and low-grade localized prostate cancer. The company also has an extensive patent portfolio covering its investigational drug as well as other therapeutic and diagnostic indications. It also has U.S. and patent rights for the use of statin drugs for the treatment and prevention of Alzheimer's disease. The company operates in one reportable segment, focused on researching and developing products for the aging population.